Transplantation News

Researchers at Medical University of South Carolina have developed a telehealth platform that they deemed successful at ensuring the kidney transplantation process continues during the COVID-19 pandemic.

President Donald J. Trump today approved a legislative package that includes lifetime coverage of immunosuppressants for kidney transplant recipients.

For kidney transplant recipients who were HIV positive, switching from calcineurin inhibitors to belatacept conferred a variety of benefits, including improved allograft function, according to a study from France.

The U.S. Senate voted in favor of legislation that extends Medicare coverage of immunosuppressants to all kidney transplant recipients, regardless of age, and ensures these medications are covered for life.

An analysis of data from the United Network for Organ Sharing suggests the COVID-19 pandemic has had a significant impact on transplantation in the United States, especially in the initial months.

A published study found kidney biopsies performed in the United States did not accurately predict allograft survival or overall organ quality.

Legislation that offers lifetime immunosuppressive drug coverage for Medicare patients who receive a kidney transplant regardless of age has passed the U.S. House of Representatives.

On Nov. 20, CMS issued a final rule regarding how the performance of organ procurement organizations is measured in the United States.

Certain social determinants of health impacted how patients viewed the care they received and their quality of life following kidney transplantation, according to research presented at the virtual ASN Kidney Week.

A recent analysis by the Congressional Budget Office estimates Medicare could save $400 million in the course of 10 years if lifetime immunosuppressive drug coverage were offered to Medicare patients with a kidney transplant.